Osmotica is committed to developing pharmaceuticals that address unmet medical needs through our ongoing development programs. This is accomplished through clinical trials, subsequent regulatory approval, and commercialization of our products. Clinical trials are used to evaluate investigational new treatments to allow Osmotica to generate the safety and efficacy information required to obtain marketing approval, and to make products available to the broader patient population.
To learn more about clinical trials that are currently underway and to find out if an Osmotica study is enrolling patients in your area or with your condition, please visit clinicaltrials.gov.
We are evaluating arbaclofen ER for spasticity in multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus and muscular rigidity.
We are studying RVL-1201 for the treatment of acquired blepharoptosis, or droopy eyelid. We are currently conducting a second Phase III clinical trial of RVL-1201 for acquired blepharoptosis.
Expanded Use Policy
Osmotica Pharmaceuticals plc does not currently provide unapproved medicines through expanded use programs. The only way for patients to access investigational therapies in development by Osmotica is through participation in clinical trials submitted to the US Food and Drug Administration (FDA) or other regulatory authorities.